Q1 Earnings Forecast for Korro Bio Issued By HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Korro Bio in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($2.54) per share for the quarter, down from their previous estimate of ($2.45). HC Wainwright currently has a “Buy” rating and a $115.00 price target on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.67) EPS, Q3 2025 earnings at ($2.82) EPS, Q4 2025 earnings at ($2.97) EPS and FY2025 earnings at ($11.00) EPS.

A number of other research analysts have also commented on the company. Royal Bank of Canada cut their price target on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday, March 19th. Oppenheimer began coverage on shares of Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Korro Bio has a consensus rating of “Buy” and an average target price of $142.57.

Korro Bio Stock Performance

Shares of NASDAQ:KRRO opened at $23.76 on Monday. The business has a 50 day moving average price of $29.88 and a 200 day moving average price of $41.37. Korro Bio has a twelve month low of $18.50 and a twelve month high of $98.00.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter.

Institutional Trading of Korro Bio

A number of hedge funds have recently modified their holdings of KRRO. Alliancebernstein L.P. acquired a new position in shares of Korro Bio in the fourth quarter valued at $26,870,000. Driehaus Capital Management LLC increased its holdings in Korro Bio by 220.3% in the 4th quarter. Driehaus Capital Management LLC now owns 494,905 shares of the company’s stock valued at $18,841,000 after buying an additional 340,410 shares during the period. Woodline Partners LP acquired a new position in shares of Korro Bio in the 4th quarter valued at $3,887,000. Franklin Resources Inc. bought a new position in shares of Korro Bio during the 4th quarter worth about $3,493,000. Finally, Tri Locum Partners LP lifted its holdings in shares of Korro Bio by 125.3% during the 4th quarter. Tri Locum Partners LP now owns 144,216 shares of the company’s stock worth $5,490,000 after acquiring an additional 80,202 shares during the period. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).